Business Context and Reporting Period
Company: Novavax, Inc. (NVAX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Reporting Period: Preliminary financial data for the year ended December 31, 2025.
Context: The filing announces an investor update scheduled for the 44th Annual J.P. Morgan Healthcare Conference. It includes preliminary, unaudited financial results for 2025 and forward-looking statements regarding strategic updates.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity for the year ended December 31, 2025. The document explicitly states that the preliminary financial data is based on available information to date and has not been audited, reviewed, or compiled by Ernst & Young LLP. Specific figures are expected to be detailed in the attached Investor Presentation (Exhibit 99.1) and the final audited financial statements.
Material Changes and Comparisons
The filing does not contain specific comparative data against the prior period (2024). It notes that actual results for the 2025 period may differ materially from the preliminary data provided. No specific material changes in operations or financial condition are quantified in the text of this 8-K.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes expectations for combined annual research and development (R&D) and selling, general, and administrative (SG&A) expenses for 2025, 2026, and 2027. Specific expense figures are not listed in the text.
- Investor Presentation: Strategic and business updates are contained in Exhibit 99.1, which is incorporated by reference but not detailed in the main body of this report.
- Risks and Uncertainties: The Company warns that actual results may differ materially from forward-looking statements due to various risks, including the potential for final audited financial statements to differ from the preliminary data. Standard risk factors referenced include those found in the most recent Form 10-K and 10-Q filings.
- Unusual Items: The filing highlights that the preliminary data is unaudited and should not be viewed as a substitute for full financial statements prepared in accordance with U.S. GAAP.
Investor Verification Checklist
- Verify the specific preliminary revenue and net loss figures for 2025 in the attached Investor Presentation (Exhibit 99.1).
- Confirm the final audited financial results once the Form 10-K for the year ended December 31, 2025, is filed.
- Review the detailed breakdown of expected R&D and SG&A expenses for 2026 and 2027 mentioned in the forward-looking statements.
- Assess the liquidity position and cash runway based on the full financial statements rather than this preliminary summary.
- Monitor the Company's website for the "Latest Investor Presentation" referenced in Item 7.01.